A biweekly <scp>DPP</scp> ‐4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial

Authors

Lixin Guo (ORCID: https://orcid.org/0000-0001-6863-1798)
Lingling Xu (ORCID: https://orcid.org/0000-0001-5760-2174)
Xiaoyan Xing (ORCID: https://orcid.org/0000-0001-9809-9202)
Xinsheng Li (ORCID: https://orcid.org/0000-0001-8186-1686)
Fangqiong Li (ORCID: https://orcid.org/0009-0005-2092-5099)
Yufeng Li (ORCID: https://orcid.org/0000-0002-5013-5849)
Liping Li (ORCID: https://orcid.org/0000-0001-7396-1310)
Zhifeng Cheng (ORCID: https://orcid.org/0000-0001-8201-9239)
Junqing Zhang (ORCID: https://orcid.org/0000-0002-8574-1945)
Qinghua He (ORCID: https://orcid.org/0000-0003-2082-5360)
Zhanhui Zhang (ORCID: https://orcid.org/0000-0003-4038-9279)
Weihong Song

Institutions

Harbin Medical University (CN)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Peking University (CN)
Peking Union Medical College Hospital (CN)
China National Pharmaceutical Group Corporation (China) (CN)
Cangzhou Central Hospital (CN)
Fourth Affiliated Hospital of Harbin Medical University (CN)
Peking University First Hospital (CN)
First Affiliated Hospital of Henan University of Science and Technology (CN)
Chenzhou First People's Hospital (CN)

Publication Details

Journal: Diabetes Obesity and Metabolism
Published: 2024-12-04
DOI: https://doi.org/10.1111/dom.16096
Citations: 2
Primary Topic: Diabetes Treatment and Management
Type: article
Field-Weighted Citation Impact: 0.72

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

A biweekly DPP ‐4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial

Lixin Guo, Lingling Xu, Xiaoyan Xing, Xinsheng Li et al.

Dec 4, 2024

2 citations

Diabetes Obesity and Metabolism

Diabetes Treatment and Management

0.72

article

A biweekly DPP ‐4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial

Lixin Guo, Lingling Xu, Xiaoyan Xing, Xinsheng Li, Fangqiong Li, Yufeng Li, Liping Li, Zhifeng Cheng, Junqing Zhang, Qinghua He, Zhanhui Zhang, Weihong Song

December 4, 2024article en

2 citations

Abstract

No abstract available for this paper.

Diabetes Obesity and MetabolismVol. 27(2)

Harbin Medical University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Peking Union Medical College Hospital (CN), China National Pharmaceutical Group Corporation (China) (CN), Cangzhou Central Hospital (CN), Fourth Affiliated Hospital of Harbin Medical University (CN), Peking University First Hospital (CN), First Affiliated Hospital of Henan University of Science and Technology (CN), Chenzhou First People's Hospital (CN)

Good health and well-being

Openalex Percentile: Top 24%

Diabetes Treatment and Management

0.72

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.